|
|
Post by bosephe on Aug 3, 2020 20:49:45 GMT -5
|
|
|
|
Post by peppy on Aug 3, 2020 20:58:45 GMT -5
mri.cts-mrp.eu/download/DK_H_2351_001_PAR.pdfBased on the review of the quality, safety and efficacy data, the Member States have granted a marketing authorisation for Procivni 25 micrograms/2 mg solution for injection, from Evolan Pharma AB. The product is indicated for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology. A comprehensive description of the indications and posology is given in the SmPC.
|
|
|
|
Post by brotherm1 on Aug 3, 2020 22:56:09 GMT -5
Peppy you lost me there. Is your post related to Aviptadil? (RLF-100)?
|
|
|
|
Post by brotherm1 on Aug 3, 2020 23:06:59 GMT -5
|
|
|
|
Post by peppy on Aug 4, 2020 4:39:00 GMT -5
Peppy you lost me there. Is your post related to Aviptadil? (RLF-100)? Procivni contains the active ingredients Aviptadil (Vasoactive Intestinal Peptide (VIP) and phentolamine intended for the treatment of erectile dysfunction. VIP acts on the veno-occlusive mechanism of erection whilst exerting little effect on the arterial inflow, whereas phentolamine increases arterial flow having little effect on the veno-occlusive mechanism. mri.cts-mrp.eu/download/DK_H_2351_001_PAR.pdf================================================================================================== ADCIRCA (tadalafil) tablets for oral administration ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability ======================================================================= brotherm1 tadalafil is also Cialis by its product name. we have been over this. turns out that which helps the pecker get blood, helps pulmonary hypertension. |
|
|
|
Post by brotherm1 on Aug 4, 2020 7:19:35 GMT -5
is tadalafil related somehow to aviptadil?
|
|
|
|
Post by peppy on Aug 4, 2020 8:02:04 GMT -5
is tadalafil related somehow to aviptadil? they are both used for erectile dysfunction. the mechanism of action. turns out they also work for pulmonary hypertension tadalafil  |
|
|
|
Post by matt on Aug 4, 2020 8:13:23 GMT -5
is tadalafil related somehow to aviptadil? Not in a pharmacological sense. Aviptadil is a peptide drug that binds to the VPAC1 receptor of ATII cells. The typical approach to treating hypertension is to inhibit the angiotensin converting enzyme which, as it name suggests, converts angiotensinogen to angiotensin and too much angiotensin (which acts on ATII cells) increases the body's production of aldosterone, causing vasoconstriction and an increase in blood pressure. Aviptadil protects ATII cells from various forms of damage including infectious agents which trigger release of inflammatory cytokines and promotes pulmonary edema, something that happens to many COVID patients. Tadalafil and its cousins (like sildenafil) are phosphodiesterase-5 inhibitors. Various PDE forms break down two biomolecules, cAMP and cGMP, which act as vasodilators. By inhibiting PDE, the action of cAMP and cGMP are prolonged which is good if the patient is hypertensive. All the PDE inhibitors are similar in that they attack a phosphodiester bond in a molecule, but the cyclic versions are the ones that act on cAMP and cGMP to promote lowering of blood pressure. As all these molecules are tissue specific, some PDE inhibitors work better in certain tissues than others. Viagra (sildenafil) was developed as an oral medication for treating systemic hypertension and failed in its Phase III clinical trial, but it did have a certain curious side effect on one specific type of tissue found in men, hence the whole field of erectile dysfunction drugs was borne proving once again that it is better to be lucky than smart. So both drugs can be used to treat PAH, but they have very different mechanisms of action. In theory both can be administered in an inhaled form, but while PAH is a chronic disease COVID is not and I would not expect a drug manufacturer to go to the trouble of reformulating the drug for short term use as an anti-infective. Besides, if a patient has COVID and is sick enough to need Aviptadil then they are already going to be in the hospital, likely the ICU or some other special treatment unit, where aerosolized drugs are frequently used as part of respiratory therapy. Treating COVID sequela does not seem to me to be a good target for Technosphere delivery of the drug. |
|
|
|
Post by wmdhunt on Aug 4, 2020 11:03:38 GMT -5
I have seen so many many possible uses for technosphere ignored, underappreciated, and never tried. This poor company just has never had a chance to prosper. I feel the leadership has given it their best but the promises have continuously proved unattainable. The absolute saddest investment I have ever made. The end of this year will have to result in tax loss selling for me I'm afraid.
|
|
|
|
Post by agedhippie on Aug 4, 2020 11:27:24 GMT -5
I have seen so many many possible uses for technosphere ignored, underappreciated, and never tried. This poor company just has never had a chance to prosper. I feel the leadership has given it their best but the promises have continuously proved unattainable. The absolute saddest investment I have ever made. The end of this year will have to result in tax loss selling for me I'm afraid. I am always curious why people do tax loss selling at the end of the year. If you really want to tax loss sell but remain invested then sell and repurchase between earnings calls, in about a month is good. That way you get your tax loss, and you get to buy back in at more or less the same price. Waiting until year end makes very little sense. |
|
|
|
Post by sweedee79 on Aug 4, 2020 12:11:16 GMT -5
I sold all of my shares in this last pump.. I haven't regretted it at all thus far.. if it gets cheap enough I may buy back in.. but I have completely lost faith in management.. and tired of looking at this stock after a decade of being disappointed... it just gets old..
I bought more MJ stock.. and looking at some airlines.. otherwise sitting in cash..
|
|
|
|
Post by mytakeonit on Aug 4, 2020 13:21:26 GMT -5
Sounds good sweedee ... meet me in Las Vegas and I'll "help" you find ways to use that cash  and maybe ... possibly make more !!! Or ... you can wait till tomorrow to see if there is a speeding train leaving the station. Whooo Whooo !!! But, that's mytakeonit |
|
|
|
Post by goyocafe on Sept 21, 2020 6:24:55 GMT -5
is tadalafil related somehow to aviptadil? Not in a pharmacological sense. Aviptadil is a peptide drug that binds to the VPAC1 receptor of ATII cells. The typical approach to treating hypertension is to inhibit the angiotensin converting enzyme which, as it name suggests, converts angiotensinogen to angiotensin and too much angiotensin (which acts on ATII cells) increases the body's production of aldosterone, causing vasoconstriction and an increase in blood pressure. Aviptadil protects ATII cells from various forms of damage including infectious agents which trigger release of inflammatory cytokines and promotes pulmonary edema, something that happens to many COVID patients. Tadalafil and its cousins (like sildenafil) are phosphodiesterase-5 inhibitors. Various PDE forms break down two biomolecules, cAMP and cGMP, which act as vasodilators. By inhibiting PDE, the action of cAMP and cGMP are prolonged which is good if the patient is hypertensive. All the PDE inhibitors are similar in that they attack a phosphodiester bond in a molecule, but the cyclic versions are the ones that act on cAMP and cGMP to promote lowering of blood pressure. As all these molecules are tissue specific, some PDE inhibitors work better in certain tissues than others. Viagra (sildenafil) was developed as an oral medication for treating systemic hypertension and failed in its Phase III clinical trial, but it did have a certain curious side effect on one specific type of tissue found in men, hence the whole field of erectile dysfunction drugs was borne proving once again that it is better to be lucky than smart. So both drugs can be used to treat PAH, but they have very different mechanisms of action. In theory both can be administered in an inhaled form, but while PAH is a chronic disease COVID is not and I would not expect a drug manufacturer to go to the trouble of reformulating the drug for short term use as an anti-infective. Besides, if a patient has COVID and is sick enough to need Aviptadil then they are already going to be in the hospital, likely the ICU or some other special treatment unit, where aerosolized drugs are frequently used as part of respiratory therapy. Treating COVID sequela does not seem to me to be a good target for Technosphere delivery of the drug. This excerpt seems to indicate the possibility of earlier use of Aviptadil, outside of the hospital setting. Big question is who is making it? Best I can find is Biogen. ”The first phase will commence with patients hospitalized for severe COVID-19 who do not yet have respiratory failure. If promising results are seen in the inpatient setting, the trial will expand to patients at home with mild and moderate COVID-19 in order to prevent the need for hospital admission. "Now that we know VIP suppresses replication of the SARS-CoV-2 virus in human lung cells, based on the outstanding work of the Oswaldo Cruz Institute (Rio de Janeiro),1 we are optimistic that treatment with VIP will not only help patients on ventilators, but will help to stop the advancement of the virus in patients with earlier stages of COVID-19. By blocking cytokine synthesis in the lung cells and increasing the production of surfactant, which is key to the lung's ability to transmit oxygen, we are hopeful that inhaled VIP will prove to be of clinical benefit across a wider array of patients suffering respiratory complications from COVID-19 infection," Professor Jonathan Javitt, MD, MPH, CEO of NeuroRx said. www.americanpharmaceuticalreview.com/1315-News/567097-FDA-Grants-Inhaled-Use-IND-for-RLF-100-for-COVID-19-to-Prevent-Respiratory-Failure/And to tie it loosely together with another post started today, Professor Jonathan Javitt, MD, MPH, CEO of NeuroRx used to walk the halls of MNKD at some point in his career, so we know he at least knows about us. |
|
|
|
Post by matt on Sept 21, 2020 7:43:06 GMT -5
Big question is who is making it? The patent holder on this drug is Relief Therapeutics, a Swiss company. I don't know who does the actual manufacturing but normally the contract manufacturer used is of little importance. NeuroRx has partnered with Relief Therapeutics to commercialize the drug for the US market. I don't think this drug has much potential for early use outside the hospital setting. If a patient has COVID or any other inflammatory promoter that triggers a cytokine storm, then they belong in the hospital (at a minimum) and preferably in the ICU. These are very sick people. |
|
|
|
Post by mango on Sept 21, 2020 10:29:59 GMT -5
Peppy you lost me there. Is your post related to Aviptadil? (RLF-100)? Procivni contains the active ingredients Aviptadil (Vasoactive Intestinal Peptide (VIP) and phentolamine intended for the treatment of erectile dysfunction. VIP acts on the veno-occlusive mechanism of erection whilst exerting little effect on the arterial inflow, whereas phentolamine increases arterial flow having little effect on the veno-occlusive mechanism. mri.cts-mrp.eu/download/DK_H_2351_001_PAR.pdf================================================================================================== ADCIRCA (tadalafil) tablets for oral administration ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability ======================================================================= brotherm1 tadalafil is also Cialis by its product name. we have been over this. turns out that which helps the pecker get blood, helps pulmonary hypertension. Yes, MannKind already has patents covering Vasoactive Intestinal Peptide. Take this recent patent for example, granted August 25, 2020 (just one of several): 4. The medicament cartridge of claim 2, wherein the active ingredient is insulin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, AZT, DDI, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, follicle stimulating hormone, vasoactive intestinal peptide, parathyroid hormone, parathyroid hormone related protein, glucagon-like peptide-1, exendin, oxyntomodulin, peptide YY, interleukin 2-inducible tyrosine kinase, Bruton's tyrosine kinase, inositol-requiring kinase 1, PC-DAC-modified derivative, or O-glycosylated forms of PC-DAC, parathyroid hormone 1-34, argatroban, or a combination thereof. patents.justia.com/patent/10751488#claims |
|
and maybe ... possibly make more !!!
